[1] Ono, T., Murakoshi, M., Suzuki, N., Iida, N., Ohdera, M., Iigo, M., Yoshida, T., Sugiyama, K., & Nishino, H. (2010). Potent anti-obesity effect of enteric-coated lactoferrin: decrease in visceral fat accumulation in Japanese men and women with abdominal obesity after 8-week administration of enteric-coated lactoferrin tablets. The British journal of nutrition, 104(11), 1688–1695. [2] Kuhara, T., Yamauchi, K., Tamura, Y., & Okamura, H. (2006). Oral administration of lactoferrin increases NK cell activity in mice via increased production of IL-18 and type I IFN in the small intestine. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 26(7), 489–499. [3] Mulder, A. M., Connellan, P. A., Oliver, C. J., Morris, C. A., & Stevenson, L. M. (2008). Bovine lactoferrin supplementation supports immune and antioxidant status in healthy human males. Nutrition research (New York, N.Y.), 28(9), 583–589. [4] Danesh J. (1999). Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Alimentary pharmacology & therapeutics, 13(7), 851–856. [5] 국가암정보센터, 내가알고싶은암 <위암> [6] Di Mario, F., Aragona, G., Dal Bó, N., Cavallaro, L., Marcon, V., Olivieri, P., Benedetti, E., Orzès, N., Marin, R., Tafner, G., Chilovi, F., De Bastiani, R., Fedrizzi, F., Franceschi, M., Salvat, M. H., Monica, F., Piazzi, L., Valiante, F., Vecchiati, U., Cavestro, G. M., … Gastrointestinal Study Unit (GISU) (2006). Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. Alimentary pharmacology & therapeutics, 23(8), 1235–1240. |